A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with gastric cancer (also known as stomach cancer) or gastroesophageal junction cancer (GEJ cancer). GEJ is where the tube that carries food (esophagus) joins the stomach. This study is for people with gastric or GEJ cancer that has sp

Trial Details

NCT ID
NCT07673887
Phase
PHASE3
Sponsor
Astellas Pharma Global Development, Inc.
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • ASP2138
  • Pembrolizumab
  • Oxaliplatin
  • Capecitabine
  • Folinic acid
  • 5-FU
Locations (sample)
  • Saint Louis Park, Minnesota, United States|44.9483,-93.34801
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangzhou, China|23.11667,113.25
  • Kashiwa, Chiba, Japan|35.86224,139.97732
  • Matsuyama, Ehime, Japan|33.83916,132.76574

Key Eligibility Criteria

  • Participant has histologically or cytologically confirmed gastric or GEJ adenocarcinoma.
  • Participant has radiographically confirmed, locally advanced unresectable or metastatic disease within 28 days prior to randomization.
  • Participant has predicted life expectancy \>= 12 weeks.
  • Female participant is not pregnant and at least 1 of the following conditions apply:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →